Lates News

Every AI Express news, Pacific on November 2 released a research report, giving Aoxiang Pharmaceutical (603229.SH) a "buy" rating. The rating reasons mainly include: 1) Q3 revenue declined year-on-year, gross margin increased slightly year-on-year; 2) Research and development investment continues to increase, with research and development expenses in Q1-Q3 reaching a record high; 3) Formulations will enter the harvest period, creating the third growth curve. (Daily Economic News)